U.S. Markets open in 3 hrs 2 mins

Stem Cell Collaboration Results Push Cellect Biotechnology Shares Higher, Full Analysis

NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cellect Biotechnology Ltd. (APOP) is a biotechnology company, focused on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel.

On March 11, 2019, Cellect Biotechnology, announced preliminary results from its collaboration with Cell2in, a privately-held South Korean company focused on improving the quality of stem cells.

Get the details of the newest stem cell data from APOP in this report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/apop/

Cellect is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. Cellect Biotechnology Ltd. has a collaboration with the Washington University in determining the safety and tolerability in Phase I/II study using ApoGraft for bone marrow transplantations in the United States.

Read about Cellect, get the financial data and the prospects for Apotainer READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/apop/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source



View source version on accesswire.com:
https://www.accesswire.com/538639/Stem-Cell-Collaboration-Results-Push-Cellect-Biotechnology-Shares-Higher-Full-Analysis